Role of CD21 antigen in diffuse large B‐cell lymphoma and its clinical significance
Summary Recent advances in immunological and molecular technology have prompted proposals to change tumour classification and treatment strategies. Cell surface antigens are now easy to access, and tumour origins and clinical characteristics are now readily identifiable. However, in diffuse large B‐...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2004-11, Vol.127 (4), p.416-424 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 424 |
|---|---|
| container_issue | 4 |
| container_start_page | 416 |
| container_title | British journal of haematology |
| container_volume | 127 |
| creator | Otsuka, Masaki Yakushijin, Yoshihiro Hamada, Makoto Hato, Takaaki Yasukawa, Masaki Fujita, Sigeru |
| description | Summary
Recent advances in immunological and molecular technology have prompted proposals to change tumour classification and treatment strategies. Cell surface antigens are now easy to access, and tumour origins and clinical characteristics are now readily identifiable. However, in diffuse large B‐cell lymphoma (DLBCL), one of the heterogeneous forms of haematological malignancy, the clinical significance of tumour surface antigens has not been well documented. We analysed the tumour surface antigens of 50 tumours from newly diagnosed DLBCL patients by flow cytometry in accordance with their clinical characteristics and followed the patients for a median 3·7 years. Statistical analysis showed that CD21 expression was significantly negatively associated with mortality in DLBCL (CD21 negative versus positive; relative risk = 2·36, P |
| doi_str_mv | 10.1111/j.1365-2141.2004.05226.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67033620</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67033620</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5386-cfe974b8320fb70f9ca58b8346812e8e9dab76aae4b11791f5404072049b2d193</originalsourceid><addsrcrecordid>eNqNkMFu1DAQhi0EotvCKyALCW4JM3bs2AcOdCkUVAkJ0bPlJPbilZMs8UZ0bzwCz8iT4LArKnFiLjOWvxn9-gihCCXmerUtkUtRMKywZABVCYIxWd49IKu_Hw_JCgDqAqFSZ-Q8pS0AchD4mJyhEAw1qhW5_TxGR0dP128ZUjvsw8YNNAy0C97PydFop42jl79-_GxdjDQe-t3XsbcZ7WjYJ9rGMITWRprCZgg-j0PrnpBH3sbknp76Bbl9d_VlfV3cfHr_Yf3mpmgFV7JovdN11SjOwDc1eN1aofKzkgqZU053tqmlta5qEGuNXlRQQc2g0g3rUPML8vJ4dzeN32aX9qYPaclpBzfOycgaOJcMMvj8H3A7ztOQsxnUSmomZZ0hdYTaaUxpct7sptDb6WAQzOLdbM2i1yx6zeLd_PFu7vLqs9P9ueldd794Ep2BFyfApmzLT1lTSPecZFxwzTP3-sh9D9Ed_juAufx4vUz8N3NYnDU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198692667</pqid></control><display><type>article</type><title>Role of CD21 antigen in diffuse large B‐cell lymphoma and its clinical significance</title><source>Wiley-Blackwell Free Backfiles(OpenAccess)</source><source>MEDLINE</source><source>Wiley Online Library</source><source>EZB Electronic Journals Library</source><creator>Otsuka, Masaki ; Yakushijin, Yoshihiro ; Hamada, Makoto ; Hato, Takaaki ; Yasukawa, Masaki ; Fujita, Sigeru</creator><creatorcontrib>Otsuka, Masaki ; Yakushijin, Yoshihiro ; Hamada, Makoto ; Hato, Takaaki ; Yasukawa, Masaki ; Fujita, Sigeru</creatorcontrib><description>Summary
Recent advances in immunological and molecular technology have prompted proposals to change tumour classification and treatment strategies. Cell surface antigens are now easy to access, and tumour origins and clinical characteristics are now readily identifiable. However, in diffuse large B‐cell lymphoma (DLBCL), one of the heterogeneous forms of haematological malignancy, the clinical significance of tumour surface antigens has not been well documented. We analysed the tumour surface antigens of 50 tumours from newly diagnosed DLBCL patients by flow cytometry in accordance with their clinical characteristics and followed the patients for a median 3·7 years. Statistical analysis showed that CD21 expression was significantly negatively associated with mortality in DLBCL (CD21 negative versus positive; relative risk = 2·36, P < 0·05). As a result of these clinical observations, we generated CD21‐overexpressed (CD21+) lymphoma cell lines after gene transfection and analysed tumour cell growth in vivo in immunocompromised mice. Mice challenged with vector‐only transfectants and parental cells as controls died within 50 d. In contrast, mice injected with CD21+ transfectants exhibited significantly reduced tumour growth and 83% survived long term (versus control groups; P < 0·05). Interestingly, all established CD21+ transfectants (six clones from different bulks) showed homotypic aggregation during in vitro cell culture, and anti‐CD21 antibodies did not block this aggregation. Expression of CD21 is strongly associated with increased survival in DLBCL in vivo. CD21 expression may be indirectly concerned with the expression of additional cell adhesion molecules.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/j.1365-2141.2004.05226.x</identifier><identifier>PMID: 15521918</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Animals ; Biological and medical sciences ; CD21 ; Cell Division ; Cell Line, Tumor ; diffuse large B‐cell lymphoma ; Disease-Free Survival ; Female ; Flow Cytometry ; Hematologic and hematopoietic diseases ; Hematology ; homotypic aggregation ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, B-Cell - immunology ; Lymphoma, B-Cell - mortality ; Lymphoma, B-Cell - pathology ; Lymphoma, Large B-Cell, Diffuse - immunology ; Lymphoma, Large B-Cell, Diffuse - mortality ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Middle Aged ; Neoplasm Transplantation ; Phenotype ; Prognosis ; Receptors, Complement 3d - metabolism ; Transfection</subject><ispartof>British journal of haematology, 2004-11, Vol.127 (4), p.416-424</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Nov 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5386-cfe974b8320fb70f9ca58b8346812e8e9dab76aae4b11791f5404072049b2d193</citedby><cites>FETCH-LOGICAL-c5386-cfe974b8320fb70f9ca58b8346812e8e9dab76aae4b11791f5404072049b2d193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2141.2004.05226.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2141.2004.05226.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16235393$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15521918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Otsuka, Masaki</creatorcontrib><creatorcontrib>Yakushijin, Yoshihiro</creatorcontrib><creatorcontrib>Hamada, Makoto</creatorcontrib><creatorcontrib>Hato, Takaaki</creatorcontrib><creatorcontrib>Yasukawa, Masaki</creatorcontrib><creatorcontrib>Fujita, Sigeru</creatorcontrib><title>Role of CD21 antigen in diffuse large B‐cell lymphoma and its clinical significance</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Recent advances in immunological and molecular technology have prompted proposals to change tumour classification and treatment strategies. Cell surface antigens are now easy to access, and tumour origins and clinical characteristics are now readily identifiable. However, in diffuse large B‐cell lymphoma (DLBCL), one of the heterogeneous forms of haematological malignancy, the clinical significance of tumour surface antigens has not been well documented. We analysed the tumour surface antigens of 50 tumours from newly diagnosed DLBCL patients by flow cytometry in accordance with their clinical characteristics and followed the patients for a median 3·7 years. Statistical analysis showed that CD21 expression was significantly negatively associated with mortality in DLBCL (CD21 negative versus positive; relative risk = 2·36, P < 0·05). As a result of these clinical observations, we generated CD21‐overexpressed (CD21+) lymphoma cell lines after gene transfection and analysed tumour cell growth in vivo in immunocompromised mice. Mice challenged with vector‐only transfectants and parental cells as controls died within 50 d. In contrast, mice injected with CD21+ transfectants exhibited significantly reduced tumour growth and 83% survived long term (versus control groups; P < 0·05). Interestingly, all established CD21+ transfectants (six clones from different bulks) showed homotypic aggregation during in vitro cell culture, and anti‐CD21 antibodies did not block this aggregation. Expression of CD21 is strongly associated with increased survival in DLBCL in vivo. CD21 expression may be indirectly concerned with the expression of additional cell adhesion molecules.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>CD21</subject><subject>Cell Division</subject><subject>Cell Line, Tumor</subject><subject>diffuse large B‐cell lymphoma</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>homotypic aggregation</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, B-Cell - immunology</subject><subject>Lymphoma, B-Cell - mortality</subject><subject>Lymphoma, B-Cell - pathology</subject><subject>Lymphoma, Large B-Cell, Diffuse - immunology</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Middle Aged</subject><subject>Neoplasm Transplantation</subject><subject>Phenotype</subject><subject>Prognosis</subject><subject>Receptors, Complement 3d - metabolism</subject><subject>Transfection</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMFu1DAQhi0EotvCKyALCW4JM3bs2AcOdCkUVAkJ0bPlJPbilZMs8UZ0bzwCz8iT4LArKnFiLjOWvxn9-gihCCXmerUtkUtRMKywZABVCYIxWd49IKu_Hw_JCgDqAqFSZ-Q8pS0AchD4mJyhEAw1qhW5_TxGR0dP128ZUjvsw8YNNAy0C97PydFop42jl79-_GxdjDQe-t3XsbcZ7WjYJ9rGMITWRprCZgg-j0PrnpBH3sbknp76Bbl9d_VlfV3cfHr_Yf3mpmgFV7JovdN11SjOwDc1eN1aofKzkgqZU053tqmlta5qEGuNXlRQQc2g0g3rUPML8vJ4dzeN32aX9qYPaclpBzfOycgaOJcMMvj8H3A7ztOQsxnUSmomZZ0hdYTaaUxpct7sptDb6WAQzOLdbM2i1yx6zeLd_PFu7vLqs9P9ueldd794Ep2BFyfApmzLT1lTSPecZFxwzTP3-sh9D9Ed_juAufx4vUz8N3NYnDU</recordid><startdate>200411</startdate><enddate>200411</enddate><creator>Otsuka, Masaki</creator><creator>Yakushijin, Yoshihiro</creator><creator>Hamada, Makoto</creator><creator>Hato, Takaaki</creator><creator>Yasukawa, Masaki</creator><creator>Fujita, Sigeru</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200411</creationdate><title>Role of CD21 antigen in diffuse large B‐cell lymphoma and its clinical significance</title><author>Otsuka, Masaki ; Yakushijin, Yoshihiro ; Hamada, Makoto ; Hato, Takaaki ; Yasukawa, Masaki ; Fujita, Sigeru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5386-cfe974b8320fb70f9ca58b8346812e8e9dab76aae4b11791f5404072049b2d193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>CD21</topic><topic>Cell Division</topic><topic>Cell Line, Tumor</topic><topic>diffuse large B‐cell lymphoma</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>homotypic aggregation</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, B-Cell - immunology</topic><topic>Lymphoma, B-Cell - mortality</topic><topic>Lymphoma, B-Cell - pathology</topic><topic>Lymphoma, Large B-Cell, Diffuse - immunology</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Middle Aged</topic><topic>Neoplasm Transplantation</topic><topic>Phenotype</topic><topic>Prognosis</topic><topic>Receptors, Complement 3d - metabolism</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Otsuka, Masaki</creatorcontrib><creatorcontrib>Yakushijin, Yoshihiro</creatorcontrib><creatorcontrib>Hamada, Makoto</creatorcontrib><creatorcontrib>Hato, Takaaki</creatorcontrib><creatorcontrib>Yasukawa, Masaki</creatorcontrib><creatorcontrib>Fujita, Sigeru</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Otsuka, Masaki</au><au>Yakushijin, Yoshihiro</au><au>Hamada, Makoto</au><au>Hato, Takaaki</au><au>Yasukawa, Masaki</au><au>Fujita, Sigeru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of CD21 antigen in diffuse large B‐cell lymphoma and its clinical significance</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2004-11</date><risdate>2004</risdate><volume>127</volume><issue>4</issue><spage>416</spage><epage>424</epage><pages>416-424</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Summary
Recent advances in immunological and molecular technology have prompted proposals to change tumour classification and treatment strategies. Cell surface antigens are now easy to access, and tumour origins and clinical characteristics are now readily identifiable. However, in diffuse large B‐cell lymphoma (DLBCL), one of the heterogeneous forms of haematological malignancy, the clinical significance of tumour surface antigens has not been well documented. We analysed the tumour surface antigens of 50 tumours from newly diagnosed DLBCL patients by flow cytometry in accordance with their clinical characteristics and followed the patients for a median 3·7 years. Statistical analysis showed that CD21 expression was significantly negatively associated with mortality in DLBCL (CD21 negative versus positive; relative risk = 2·36, P < 0·05). As a result of these clinical observations, we generated CD21‐overexpressed (CD21+) lymphoma cell lines after gene transfection and analysed tumour cell growth in vivo in immunocompromised mice. Mice challenged with vector‐only transfectants and parental cells as controls died within 50 d. In contrast, mice injected with CD21+ transfectants exhibited significantly reduced tumour growth and 83% survived long term (versus control groups; P < 0·05). Interestingly, all established CD21+ transfectants (six clones from different bulks) showed homotypic aggregation during in vitro cell culture, and anti‐CD21 antibodies did not block this aggregation. Expression of CD21 is strongly associated with increased survival in DLBCL in vivo. CD21 expression may be indirectly concerned with the expression of additional cell adhesion molecules.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>15521918</pmid><doi>10.1111/j.1365-2141.2004.05226.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2004-11, Vol.127 (4), p.416-424 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67033620 |
| source | Wiley-Blackwell Free Backfiles(OpenAccess); MEDLINE; Wiley Online Library; EZB Electronic Journals Library |
| subjects | Animals Biological and medical sciences CD21 Cell Division Cell Line, Tumor diffuse large B‐cell lymphoma Disease-Free Survival Female Flow Cytometry Hematologic and hematopoietic diseases Hematology homotypic aggregation Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, B-Cell - immunology Lymphoma, B-Cell - mortality Lymphoma, B-Cell - pathology Lymphoma, Large B-Cell, Diffuse - immunology Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - pathology Male Medical sciences Mice Mice, Inbred BALB C Middle Aged Neoplasm Transplantation Phenotype Prognosis Receptors, Complement 3d - metabolism Transfection |
| title | Role of CD21 antigen in diffuse large B‐cell lymphoma and its clinical significance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A38%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20CD21%20antigen%20in%20diffuse%20large%20B%E2%80%90cell%20lymphoma%20and%20its%20clinical%20significance&rft.jtitle=British%20journal%20of%20haematology&rft.au=Otsuka,%20Masaki&rft.date=2004-11&rft.volume=127&rft.issue=4&rft.spage=416&rft.epage=424&rft.pages=416-424&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/j.1365-2141.2004.05226.x&rft_dat=%3Cproquest_cross%3E67033620%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198692667&rft_id=info:pmid/15521918&rfr_iscdi=true |